Emergent BioSolutions Q4 revenue falls

Emergent BioSolutions

26/02/2026 21:57

Overview

Biodefense firm's Q4 revenue fell

Company reported Q4 net loss of $54.6 mln, reflecting ongoing market pressures

Outlook

Emergent forecasts 2026 total revenues between $720 mln and $760 mln

Company expects 2026 adjusted EBITDA between $135 mln and $155 mln

Result Drivers

NALAXONE SALES DECLINE - Q4 revenues from Naloxone products decreased 41% due to increased competition from generics impacting price and unit sales

ANTHRAX MCM GROWTH - Revenues from Anthrax MCM products increased 64% due to timing of U.S. government and foreign sales

SMALLPOX MCM SALES DROP - Smallpox MCM revenues fell 54% due to timing of U.S. government and international sales

Company press release: ID:nGNX125tqB

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Miss
$148.70 mln
$217.50 mln (2 Analysts)
Q4 Adjusted EPS
-$0.43
Q4 Adjusted Net Income
Miss
-$22.70 mln
-$12.83 mln (2 Analysts)
Q4 Net Income
-$54.60 mln
Q4 Adjusted EBITDA
Beat
$11.20 mln
$7.10 mln (1 Analyst)
Q4 Gross Margin
30.00%
Q4 Adjusted Gross Margin
43.00%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Emergent BioSolutions Inc is $13.50, about 22.6% above its February 25 closing price of $11.01

The stock recently traded at 3 times the next 12-month earnings vs. a P/E of 3 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)